PT  - JOURNAL ARTICLE
AU  - Furukawa, Koichi
AU  - Tjan, Lidya Handayani
AU  - Sutandhio, Silvia
AU  - Kurahashi, Yukiya
AU  - Iwata, Sachiyo
AU  - Tohma, Yoshiki
AU  - Sano, Shigeru
AU  - Nakamura, Sachiko
AU  - Nishimura, Mitsuhiro
AU  - Arii, Jun
AU  - Kiriu, Tatsunori
AU  - Yamamoto, Masatsugu
AU  - Nagano, Tatsuya
AU  - Nishimura, Yoshihiro
AU  - Mori, Yasuko
TI  - Cross-neutralizing activity against SARS-CoV-2 variants in COVID-19 patients: Comparison of four waves of the pandemic in Japan
AID  - 10.1101/2021.06.10.21258682
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.10.21258682
4099  - http://medrxiv.org/content/early/2021/06/13/2021.06.10.21258682.short
4100  - http://medrxiv.org/content/early/2021/06/13/2021.06.10.21258682.full
AB  - In March 2021, Japan is facing a 4th wave of SARS-CoV-2 infection. To prevent further spread of infection, sera cross-neutralizing activity of patients previously infected with conventional SARS-CoV-2 against novel variants is important but is not firmly established. We investigated the neutralizing potency of 81 COVID-19 patients’ sera from 4 waves of pandemic against SARS-CoV-2 variants using their authentic viruses. Most sera had neutralizing activity against all variants, showing similar activity against B.1.1.7 and D614G, but lower activity especially against B.1.351. In the 4th wave, sera-neutralizing activity against B.1.1.7 was significantly higher than that against any other variants, including D614G. The cross-neutralizing activity of convalescent sera was effective against all variants but was potentially weaker for B.1.351.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Hyogo Prefectural Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethical committees of Kobe University Graduate School of Medicine (approval code: B200200) and Hyogo Prefectural Kakogawa Medical Center.This study was a retrospective observational investigation and was carried out after written consent was obtained from the subjects or by the opt-out method when it was difficult to get written consent due to the disease severity. No statistical methods were used to predetermine the sample size.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors declare no conflicts of interest with respect to this.